Some embodiments of the invention include methods of using a compound such as Formula (I), Formula (II), or I-1 (e.g., in compositions or in pharmaceutical compositions) for treating diseases (e.g., cancer such as chemo-resistant cancer or cancer-therapy-resistant cancer). Additional embodiments of the invention are also discussed herein.

Some embodiments of the invention include methods of using a compound such as Formula (I), Formula (II), or I-1 (e.g., in compositions or in pharmaceutical compositions) for treating diseases (e.g., cancer such as chemo-resistant cancer or cancer-therapy-resistant cancer). Additional embodiments of the invention are also discussed herein.

The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.

The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.

The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.

The compositions of the various embodiments include benzoyl peroxide and Hest G-18-0. The methods of this invention include treating acne, increasing the solubility of benzoyl peroxide, and treating the skin. Embodiments are also directed to a dual chamber package comprising a chamber for benzoyl peroxide and a chamber for Hest G-18-0.

The compositions of the various embodiments include benzoyl peroxide and Hest G-18-0. The methods of this invention include treating acne, increasing the solubility of benzoyl peroxide, and treating the skin. Embodiments are also directed to a dual chamber package comprising a chamber for benzoyl peroxide and a chamber for Hest G-18-0.

The present invention provides a new inhaler device for the storage and/or administration of inhalable liquids to a patient offering one or more advantages or improvements over known inhalers, particularly inhalers for the delivery of halogenated volatile liquids such as methoxyflurane for use as an analgesic.

The present invention provides a new inhaler device for the storage and/or administration of inhalable liquids to a patient offering one or more advantages or improvements over known inhalers, particularly inhalers for the delivery of halogenated volatile liquids such as methoxyflurane for use as an analgesic.

Disclosed is an antibiotic aqueous dispersion composition including as an active ingredient zinc pyrithione and, at least one subsidiary antiseptic selected from the group consisting of thiamine dilauryl sulphate (TDS), a salt and glyceryl monoalkyl ether. The composition has excellent stability and wide antibiotic or antiseptic spectra to bacteria and fungus.